Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1receptor modulator: Favorable impact of dose up-titration
Author:
Affiliation:
1. Department of Clinical Pharmacology; Actelion Pharmaceuticals Ltd; Allschwil Switzerland
2. Clinical Research Services Kiel GmbH; Kiel Germany
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Reference35 articles.
1. Fingolimod for relapsing multiple sclerosis: an update;Horga;Expert Opin Pharmacother.,2010
2. Dissecting the role of the S1P/S1PR axis in health and disease;Aarthi;J Dent Res.,2011
3. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs;Cyster;Annu Rev Immunol.,2005
4. Sphingosine-1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology;Brinkmann;Pharmacol Ther.,2007
5. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients;Schwab;Science,2005
Cited by 61 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Icanbelimod (CBP-307), a next-generation Sphingosine-1-phosphate receptor modulator, in healthy men: pharmacokinetics, pharmacodynamics, safety, and tolerability in a randomized trial in Australia;Frontiers in Immunology;2024-06-17
2. Cardiovascular Evaluation of Etrasimod, a Selective Sphingosine 1‐phosphate Receptor Modulator, in Healthy Adults: Results of a Randomized, Thorough QT/QTc Study;Clinical Pharmacology in Drug Development;2024-03-05
3. Reversible oxidation/reduction steps in the metabolic degradation of the glycerol side chain of the S1P 1 modulator ponesimod;Xenobiotica;2024-03
4. Safety, Pharmacokinetics, and Pharmacodynamics of Etrasimod: Single and Multiple Ascending Dose Studies in Healthy Adults;Clinical Pharmacology in Drug Development;2024-02-12
5. Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses;Clinical Gastroenterology and Hepatology;2023-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3